Liron Caplan
Overview
Explore the profile of Liron Caplan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
2878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sen R, Caplan L, Danila M
Curr Opin Rheumatol
. 2023 Dec;
36(2):95-107.
PMID: 38126207
Purpose Of Review: This review summarizes the recent evidence available regarding the epidemiology of cardiovascular disease in spondyloarthritis (SpA), including the effect of disease modifying drugs on cardiovascular risk. Recent...
2.
Humphrey M, Russell L, Danila M, Fink H, Guyatt G, Cannon M, et al.
Arthritis Care Res (Hoboken)
. 2023 Oct;
75(12):2405-2419.
PMID: 37884467
Objective: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5...
3.
Humphrey M, Russell L, Danila M, Fink H, Guyatt G, Cannon M, et al.
Arthritis Rheumatol
. 2023 Oct;
75(12):2088-2102.
PMID: 37845798
Objective: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5...
4.
Rosenzweig H, Vance E, Asare-Konadu K, Koney K, Lee E, Deodhar A, et al.
Ann Rheum Dis
. 2023 Oct;
83(2):214-222.
PMID: 37813481
Objective: Polymorphisms in the antifungal signalling molecule are associated with ankylosing spondylitis (AS). Here, we investigated the cellular mechanism by which CARD9 controls pathogenic Th17 responses and the onset of...
5.
Stoll M, Huizar E, Caplan L
J Rheumatol
. 2023 Feb;
50(4):466-468.
PMID: 36725058
No abstract available.
6.
Sen R, Caplan L
Curr Opin Pharmacol
. 2022 Nov;
67:102307.
PMID: 36335714
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that predominantly affects the axial skeleton and is characterized by inflammatory back pain. While much has been published regarding non-steroidal anti-inflammatory drugs...
7.
Sen R, Kim E, Napier R, Cheng E, Fernandez A, Manning E, et al.
Arthritis Rheumatol
. 2022 Sep;
75(2):232-241.
PMID: 36053919
Objectives: This study was conducted to assess the utility of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting radiographic sacroiliitis and active disease in axial spondyloarthritis (SpA) and to...
8.
Caplan A, Caplan L
Rheum Dis Clin North Am
. 2022 Aug;
48(3):589-599.
PMID: 35953225
The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach has emerged as an extremely common method for rating quality of a body of evidence in systematic reviews and for...
9.
Maksymowych W, Lambert R, Caplan L, Van den Bosch F, Ostergaard M
Nat Rev Rheumatol
. 2022 May;
18(8):481-489.
PMID: 35562426
Concerns have been raised that randomized placebo-controlled trials (RCTs) in non-radiographic axial spondyloarthritis (nr-axSpA) might be failing to identify patients that best show differences in clinical response rates between those...
10.
Edward J, Josey K, Bahn G, Caplan L, Reusch J, Reaven P, et al.
Cardiovasc Diabetol
. 2022 Apr;
21(1):58.
PMID: 35477454
Background: Evidence to guide type 2 diabetes treatment individualization is limited. We evaluated heterogeneous treatment effects (HTE) of intensive glycemic control in type 2 diabetes patients on major adverse cardiovascular...